Xinhui

What Xinhui does

Beijing Xinhui Puri Technology Development Co., Ltd. (北京鑫汇普瑞科技发展有限公司, branded as "Xinhui" or "鑫汇科技") is a privately held Chinese technology company founded in 2004 and headquartered in the Zhongguancun Science and Technology Park, Changping District, Beijing. The company develops the MicroID (\u5fae\u68c0\u7cfb\u7edf) microbial detection system, a proprietary MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry) software and spectral database jointly developed with the China CDC Infectious Disease Control Institute and transferred to Xinhui in full under a 2017 technology transfer agreement. MicroID's reference database contains spectral profiles for 80,000+ strains covering 3,800+ species and genus, with pathogen references specifically calibrated to Chinese microbial strains, differentiating it from European-skewed competitors such as the Bruker Biotyper and bioMérieux Saramis systems. The system supports a cloud-computing identification mode (\u5fae\u751f\u7269\u68c0\u6d4b\u4e91\u8ba1\u7b97\u5e73\u53f0) that runs parallel identifications across multiple connected servers and is compatible with three major MALDI-TOF MS instrument brands (Shimadzu AXIMA Assurance, Bruker Microflex LT, and Xiamen microTyper).

The company operates a dual business model combining enterprise software/database licensing with fee-for-service testing. Revenue stream one is the sale and licensing of the MicroID software and database to laboratories, hospitals, and food safety companies operating their own MALDI-TOF MS instruments. Revenue stream two is delivered through the company's wholly-owned subsidiary, Beijing Xinhui Maike Biotechnology Co., Ltd. (北京鑫汇迈科生物科技有限公司, established 2016), which operates as a CMA- and CNAS-certified third-party testing laboratory providing microbial detection services across food safety, drinking water, veterinary, and sanitary product applications, plus gene detection services using Oxford Nanopore sequencing. The customer base spans food and beverage manufacturers, clinical and hospital laboratories, inspection and quarantine bureaus, and veterinary/agricultural testing agencies.

Xinhui has secured dual scientific recognition for its pathogen mass spectrometry identification system, winning the 2018 Huaxia Medical Science and Technology Award (Second Prize) and the 2018 Chinese Medical Science and Technology Award (Third Prize), and was a Phase 3 finalist in the 2019 Walmart Food Safety Innovation Platform. The firm was designated a Beijing "Specialized, Refined, Differential and Innovative Enterprise" (专精特新企业) in 2022. The company is founder-led by Chairman Zhu Jiaqiang (朱家强), bootstrapped with only ~$1.97M in disclosed equity funding across two rounds in 2016 and 2017, and operates exclusively within the Chinese domestic market with a single Beijing-based R&D and testing footprint.

Name

Xinhui

Legal name

北京鑫汇普瑞科技发展有限公司

Website

https://xhpr.net

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

1–10 employees

Short description

Xinhui is a privately held Beijing-based technology company that develops the MicroID MALDI-TOF MS microbial detection software and database, and operates a CMA/CNAS-certified third-party testing laboratory through its subsidiary, serving clinical, food safety, inspection, and veterinary customers in China.

Ownership category

akta.pro rank

Product category

Microbial Diagnostic Software

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511)

SIC

Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071)

akta.pro primary industry

Microbiology LIS/LIMS (HLACAMAD)

akta.pro secondary industries

Microbiology & Infectious Disease Diagnostics (Culture/ID/AST) (HLAHAAAC), Microbiology & Infectious Disease Testing Laboratories (HLAFAMAD)

Keywords

• Microbial detection software
• Mass spectrometry identification
• Pathogen identification database
• Food safety testing
• Clinical diagnostic software

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. MicroID Software Licensing and Database Services: License fees for the MicroID microbial detection software system and database, sold to laboratories and hospitals that operate their own MALDI-TOF MS instruments. Revenue from software licensing, database access, and technical support services.
2. Third-Party Microbial Testing Services: 北京鑫汇迈科生物科技有限公司 operates as a certified third-party testing laboratory (CMA/CNAS) providing fee-for-service microbial testing including food safety testing, drinking water testing, veterinary testing, and custom MALDI-TOF MS microbial identification services.
3. Gene Detection Services: Gene detection services including pathogen gene testing, AIV subtypes (H5/H7/H9), and peste des petits ruminants virus diagnosis, leveraging Oxford Nanopore sequencing technology.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Xinhui develops and licenses MicroID, a domestically-developed MALDI-TOF MS microbial identification software system with a proprietary database of 80,000+ strain spectra covering 3,800+ species, co-developed with the Chinese CDC. Through its subsidiary Xinhui Maike, the company also operates a CMA/CNAS-certified third-party testing laboratory providing fee-for-service microbial and gene detection for food, water, clinical, and veterinary clients.

Product overview

Xinhui offers a unified product ecosystem centered on the MicroID (微检系统) platform — a MALDI-TOF MS microbial detection software and database system developed in partnership with the Chinese CDC. The company also operates as a third-party testing laboratory (鑫汇迈科) providing microbial testing services. The portfolio includes the core MicroID software product, a cloud-based microbial detection computing platform, and laboratory testing services for food, drinking water, feed, and sanitary products.

Differentiator

Problem solved

Functional benefit

Brands

• MicroID: Microbiological detection system (also known as MicroID or 微检系统) developed jointly with China CDC, based on MALDI-TOF MS technology for rapid microorganism identification. The system includes a proprietary database of over 80,000 strain spectra covering 3,800+ species and genera. It is China's first independently developed microbiological identification system with full intellectual property rights.

Products and services

• MicroID Microbial Detection Software and Database (微生物检测鉴定系统) A MALDI-TOF MS-based microbial identification software and database system that identifies microorganisms by comparing mass spectra against a proprietary database of 80,000+ strain spectra covering 3,800+ species. Sold to laboratories, hospitals, food companies, and inspection agencies that operate MALDI-TOF MS instruments.
• Gene Detection Services (基因检测服务) Gene detection services using Oxford Nanopore sequencing for pathogen gene testing, AIV subtype identification (H5/H7/H9), and peste des petits ruminants virus diagnosis, delivered by the Xinhui Maike laboratory.

Quantifiable outcome

• Detection speed reduced from days to minutes compared to traditional culture-based methods
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• 中国疾病预防控制中心传染病预防控制所 (China CDC Infectious Disease Control Institute)coreStrategic or Co-development PartnerStrategic co-development partner for the MicroID system. China CDC provided pathogen reference spectra and scientific validation. Formal technology transfer contract signed in February 2017, transferring complete MicroID technology to 鑫汇科技. Co-developed the 《病原菌质谱识别鉴定新型技术体系创建与应用》 which won both 华夏医学科技奖 and 中华医学科技奖 in 2018.
• 岛津企业管理（中国）有限公司 (Shimadzu China)coreTechnology or IntegrationShimadzu is a key technology partner. Three-party meeting held in December 2016 between Shimadzu Japan HQ, China CDC, and 鑫汇科技 to discuss MicroID and MALDI-TOF MS cooperation. Shimadzu's AXIMA Assurance MALDI-TOF MS is one of three instruments officially compatible with the MicroID system.
• 中国工业微生物菌种保藏管理中心 (CICC)coreStrategic or Co-development PartnerStrategic cooperation agreement reached in April 2018. CICC is China's leading industrial microbiology strain preservation and testing center. The partnership focuses on strategic cooperation in microbial strain identification and database expansion.
• 国家电力投资集团公司 (State Power Investment Corporation, SPIC)minorOthersListed as a partner on the company website. Nature of partnership is not detailed in available source material.
• 中国铝业公司 (Aluminum Corporation of China, Chalco)minorOthersListed as a partner on the company website. Nature of partnership is not detailed in available source material.
• 中国火箭军总医院 (PLA Rocket Force General Hospital)minorOthersListed as a partner on the company website. Likely a testing service client or healthcare cooperation partner.
• 中国医师协会 (Chinese Medical Doctor Association)minorOthersListed as a partner on the company website. Historical cooperation with 鑫汇科技 on hospital-related software development.
• 北京恒和医院 (Beijing Henghe Hospital)minorStrategic or Co-development PartnerCooperation discussion in April 2018 focused on Helicobacter pylori精准检测, HPV virus detection, and precision medicine research collaboration. Hospital leadership expressed high recognition of 鑫汇科技's detection technology.
• 中国食品发酵工业研究院 (China Food Fermentation Industry Research Institute)minorStrategic or Co-development PartnerBusiness exchange visit in January 2018. Both parties conducted in-depth exchanges on microbial detection technology and expressed preliminary cooperation intentions.

Scale indicators4 records

Recent moves7 records

Expansion highlights4 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Xinhui